BIO-RAD LABORATORIES, INC. BIO

Bio-Rad Laboratories’ latest supplied filing rail is led by the April 30, 2026 10-Q for the quarter ending March 31, 2026: revenue from contracts with customers was $592.1 million, operating income was $34.1 million, and net income attributable to the parent was a loss of $527.1 million. Diluted earnings per share were negative $19.55 on 27.0 million diluted shares. That is the day’s hard centre: an operating business still producing positive operating income, set against a very large reported net loss.

The company’s own 10-Q describes Bio-Rad as operating in Life Science and Clinical Diagnostics, providing scientists with specialised tools for biological research and health care specialists with products for clinical diagnostics. That product rail matters because the figures are not attached to a vague technology promise. The supplied evidence points to laboratory research tools, clinical diagnostic products, and customers whose purchasing can be shaped by reimbursement economics.

The filed balance sheet is substantial. For the period ending March 31, 2026, Bio-Rad reported $9.79 billion of assets, $2.94 billion of liabilities, and $6.85 billion of stockholders’ equity attributable to the parent. Cash and cash equivalents were $507.2 million, short-term investments were $1.06 billion, net cash provided by operating activities was $108.1 million, payments for property, plant and equipment were $30.0 million, research and development expense was $62.9 million, inventory was $770.5 million, and inventories increased by $29.9 million.

No chart route or price level is supplied in this evidence pack, so the market mechanism has to be read through the company’s SEC rail rather than through candles or support lines. The relevant public developments are named filings: the April 30, 2026 8-K announcing first quarter 2026 results and supplemental earnings materials, the April 30, 2026 10-Q, the April 24, 2026 8-K covering the April 21 annual meeting and approval of the amended Bio-Rad Laboratories, Inc. plan, the April 30 S-8, the May 13 Form SD, the May 13 Form 4, and May 11 and May 28 Form 144 filings.

The product and sales detail adds a useful operating check. Clinical Diagnostics segment sales were $363.6 million in the first quarter of 2026, up 1.9% compared with the same period in 2025, according to the 10-Q. The same filing warns that laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate. That is a concrete commercial risk: the company can supply the tools, but reimbursement can still decide how much testing happens.

What remains unproved by this source pack is market reaction, valuation, management commentary beyond the named filings, and any fresh product approval or launch not included in the rail. A deeper file would need a supplied chart route, fuller earnings presentation detail, segment margins, guidance, and direct source evidence for any product release. The current file is narrower, but it is not empty: it shows a diagnostics and life science supplier with positive operating income, heavy net loss, meaningful cash and short-term investments, active R&D spend, and a recent run of SEC events.